8-K
filed May 15, 2024, 7:59 PM ET
ticker BRNS
CIK 0001828185
other
confidence high
sentiment neutral
materiality 0.10
Barinthus shareholders approve all proposals at 2024 AGM, re-elect directors
Barinthus Biotherapeutics plc.
- Three directors re-elected: William Enright, Alex Hammacher, Robin Wright with >98% of votes cast.
- PricewaterhouseCoopers LLP reappointed as UK statutory auditors and ratified as independent auditor for FY 2024.
- Advisory vote on directors' compensation report for FY 2023 passed with ~99.8% approval.
- No dividend for FY 2023 as recommended by directors; annual accounts received.
- Broker non-votes were ~3 million shares (about 13.6% of quorum) on certain items.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Barinthus Biotherapeutics plc. shareholders approved Re-elect as a director, Robin Wright, who retires by rotation at the 2024-05-10 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2024-05-10
Exact text from the filing
To re-elect as a director, Robin Wright, who retires by rotation in accordance with the Company’s Articles of Association 18,885,204 166,609 161 3,000,133
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Barinthus Biotherapeutics plc. shareholders approved Re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company at the 2024-05-10 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2024-05-10
Exact text from the filing
To re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders 22,035,376 81 16,650 0
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Barinthus Biotherapeutics plc. shareholders approved Re-elect as a director, William Enright, who retires by rotation at the 2024-05-10 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2024-05-10
Exact text from the filing
To re-elect as a director, William Enright, who retires by rotation in accordance with the Company’s Articles of Association 18,871,704 180,109 161 3,000,133
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Barinthus Biotherapeutics plc. shareholders approved Ratify the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-05-10 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2024-05-10
Exact text from the filing
To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 22,035,421 34 16,651 1
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.7
Barinthus Biotherapeutics plc. shareholders approved Receive the U.K. statutory annual accounts and reports for fiscal year ended December 31, 2023 and note no dividend at the 2024-05-10 meeting.
- Outcome
- passed
- Meeting
- 2024-05-10
Exact text from the filing
To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2023 and to note that the Company’s directors do not recommend the payment of any dividend for the fiscal year ended December 31, 2023 19,034,966 304 16,704 3,000,133
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Barinthus Biotherapeutics plc. shareholders approved Re-elect as a director, Alex Hammacher, who retires by rotation at the 2024-05-10 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2024-05-10
Exact text from the filing
To re-elect as a director, Alex Hammacher, who retires by rotation in accordance with the Company’s Articles of Association 18,871,704 180,109 161 3,000,133
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Barinthus Biotherapeutics plc. shareholders approved Receive and approve on advisory basis the Company’s U.K. statutory directors’ compensation report for fiscal year ended December 31, 2023 at the 2024-05-10 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2024-05-10
Exact text from the filing
To receive and approve on an advisory basis the Company’s U.K. statutory directors’ compensation report for the fiscal year ended December 31, 2023 19,030,522 4,633 16,819 3,000,133
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.7
Barinthus Biotherapeutics plc. shareholders approved Authorize the Audit Committee to determine the Company’s auditors’ remuneration for fiscal year ending December 31, 2024 at the 2024-05-10 meeting.
- Outcome
- passed
- Meeting
- 2024-05-10
Exact text from the filing
To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2024 19,035,192 171 16,611 3,000,133
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.